Zevra Therapeutics, Inc.: 10-Q filed 2015-11-13

Name: Zevra Therapeutics, Inc.: 10-Q filed 2015-11-13
Creator: Zevra Therapeutics, Inc.

What Zevra Therapeutics, Inc. reported in its quarterly report filed 2015-11-13 (fiscal Q3 2015): 23 published measures, 66 facts as tagged in accession 0001564590-15-010727.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-11-13
Fiscal period: fiscal Q3 2015
Accession: 0001564590-15-010727 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Zevra Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-09-30	61,416,000	USD
At 2014-12-31	13,714,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2015-09-30	67,162,000	USD
At 2014-12-31	38,015,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-09-30	-5,746,000	USD
At 2014-12-31	-48,508,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2015-09-30	59,009,000	USD
At 2014-12-31	10,255,000	USD
At 2014-09-30	19,022,000	USD
At 2013-12-31	1,969,000	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-9,744,000	USD	92
2015-01-01 to 2015-09-30	-45,461,000	USD	273
2014-07-01 to 2014-09-30	-7,137,000	USD	92
2014-01-01 to 2014-09-30	-12,615,000	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	95,000	USD	273
2014-01-01 to 2014-09-30	19,000	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-09-30	-95,622,000	USD
At 2014-12-31	-50,160,000	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	20,000	USD	92
2015-01-01 to 2015-09-30	27,000	USD	273
2014-07-01 to 2014-09-30	-38,000	USD	92
2014-01-01 to 2014-09-30	-49,000	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-09-30	386,000	USD
At 2014-12-31	352,000	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	1,456,000	USD	273
2014-01-01 to 2014-09-30	169,000	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-6,480,000	USD	92
2015-01-01 to 2015-09-30	-15,532,000	USD	273
2014-07-01 to 2014-09-30	-4,339,000	USD	92
2014-01-01 to 2014-09-30	-8,955,000	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-09-30	59,616,000	USD
At 2014-12-31	10,278,000	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	687,000	USD	92
2015-01-01 to 2015-09-30	1,973,000	USD	273
2014-07-01 to 2014-09-30	173,000	USD	92
2014-01-01 to 2014-09-30	974,000	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-09-30	6,792,000	USD
At 2014-12-31	3,935,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	6,480,000	USD	92
2015-01-01 to 2015-09-30	15,532,000	USD	273
2014-07-01 to 2014-09-30	4,339,000	USD	92
2014-01-01 to 2014-09-30	8,955,000	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	4,328,000	USD	92
2015-01-01 to 2015-09-30	9,215,000	USD	273
2014-07-01 to 2014-09-30	3,253,000	USD	92
2014-01-01 to 2014-09-30	6,006,000	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-09-30	14,241,562	shares
At 2014-12-31	2,381,041	shares

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2015-09-30	199,000	USD
At 2014-12-31	1,616,000	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2015-09-30	607,000	USD
At 2014-12-31	23,000	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-9,724,000	USD	92
2015-01-01 to 2015-09-30	-45,434,000	USD	273
2014-07-01 to 2014-09-30	-7,175,000	USD	92
2014-01-01 to 2014-09-30	-12,664,000	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	2,152,000	USD	92
2015-01-01 to 2015-09-30	6,317,000	USD	273
2014-07-01 to 2014-09-30	1,086,000	USD	92
2014-01-01 to 2014-09-30	2,949,000	USD	273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	61,000	USD	273
2014-01-01 to 2014-09-30	56,000	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-3,244,000	USD	92
2015-01-01 to 2015-09-30	-29,902,000	USD	273
2014-07-01 to 2014-09-30	-2,836,000	USD	92
2014-01-01 to 2014-09-30	-3,709,000	USD	273

Inspect the source

Entity: Zevra Therapeutics, Inc. / CIK 0001434647
Captured: 2026-09-20T09:02:58.411Z
SEC response SHA-256: e6444155e299482d8e745cbcf52e94d14227a2668e6d953fd1eb25cffef79d18

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001434647.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))